XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue from Contracts with Customers
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
Major Products/Service Lines (in thousands)2021202020212020
    Product revenue, net(1)

$96,678 $83,661 $277,559 $238,801 
    License and royalty revenues5,395 4,883 18,087 6,457 
Total revenues$102,073 $88,544 $295,646 $245,258 
________________________________
(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the
same revenue recognition policies and judgments for all its principal products.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other includes partnerships related to other products of the Company, such as RELISTOR.
Revenue by product category on a net basis is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021
2020(1)
2021
2020(1)
   DEFINITY$57,636 $50,359 $173,448 $139,989 
   TechneLite22,680 21,113 69,252 62,560 
   Other precision diagnostics7,563 8,585 21,289 28,782 
Total precision diagnostics87,879 80,057 263,989 231,331 
Radiopharmaceutical oncology8,890 3,323 13,203 7,474 
Strategic partnerships and other5,304 5,164 18,454 6,453 
   Total revenues$102,073 $88,544 $295,646 $245,258 
________________________________
(1)The Company reclassified rebates and allowances of $5.5 million and $13.8 million within each product category, which included $5.1 million and $12.6 million for DEFINITY, $0.3 million and $0.9 million for TechneLite and $0.1 million and $0.2 million for other precision diagnostics, for the three and nine months ended September 30, 2020, respectively.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.